Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and on-going promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

    Related Conference of Drug Development in Dementia

    April 23-24, 2026

    8th World Depression Congress

    Paris, France
    May 14-15, 2026

    9th World Conference on Neuroscience

    Rome, Italy
    June 22-23, 2026

    18th Global Neurologists Meeting on Neurology and Neurosurgery

    Amsterdam, Netherlands
    June 22-23, 2026

    7th World Congress on Sleep Disorders and Therapeutics

    Amsterdam, Netherlands
    June 22-23, 2026

    38th World Conference on Neurology

    Barcelona, Spain
    June 29-30, 2026

    37th Conference on Clinical Neuroscience and Neurogenetics

    Aix-en-Provence, France
    June 29-30, 2026

    39th European Neurology Congress

    London, UK
    July 20-21, 2026

    37th World Congress on Neurology and Neuroscience

    Amsterdam, Netherlands
    July 23-24, 2026

    14th International Conference on Cannabis & Medicinal Research

    Amsterdam, Netherlands
    July 23-24, 2026

    16th Global Alzheimers Summit

    Paris, France
    September 18-19, 2026

    21st Annual Congress on Neuroscience

    Dubai, UAE

    Drug Development in Dementia Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in